REGENERON PHARMACEUTICALS, INC. Other Expenses
REGENERON PHARMACEUTICALS, INC. (REGN) reported Other Expenses of $222.00 thousand for the 3-month period ending 2016-09-30, per its 10-Q filed 2016-11-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherExpenses · last filed 2016-11-04
- REGENERON PHARMACEUTICALS, INC. other expenses for the quarter ending 2016-09-30 was $222.00K, a 82.56% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. other expenses for the quarter ending 2016-06-30 was $2.17M, a 88.26% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. other expenses for the quarter ending 2016-03-31 was $1.41M, a 80.50% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. other expenses for the quarter ending 2015-09-30 was $1.27M.
| Period end | Other Expenses 3 month | Other Expenses 6 month | Other Expenses 9 month |
|---|---|---|---|
| 2016-09-30 | $222.00K 10-Q · filed 2016-11-04 | $2.40M derived: sum of 2 quarters · filed 2016-11-04 | $3.80M 10-Q · filed 2016-11-04 |
| 2016-06-30 | $2.17M 10-Q · filed 2016-08-04 | $3.58M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $1.41M 10-Q · filed 2016-05-05 | ||
| 2015-09-30 | $1.27M 10-Q · filed 2016-11-04 | $19.79M derived: sum of 2 quarters · filed 2016-11-04 | $27.00M 10-Q · filed 2016-11-04 |
| 2015-06-30 | $18.52M 10-Q · filed 2016-08-04 | $25.73M 10-Q · filed 2016-08-04 | |
| 2015-03-31 | $7.21M 10-Q · filed 2016-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |